{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:01:50Z","timestamp":1793041310825,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically evaluate the efficacy and safety of norepinephrine in the treatment of septic shock.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Literature retrieval of eligible randomized controlled trials (RCTs) on norepinephrine in the treatment of septic shock was performed in three English databases including PubMed, Web of Science, and Medline from database establishment to October 1, 2023. The Cochrane risk bias tool was used to evaluate the quality of the included literature. RevMan 5.3 software was used for meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 14 RCTs were included in this study, and the risk of bias was low. Our meta-analysis showed that the norepinephrine group had significantly better outcomes in reducing the 28-day mortality rate (RR\u2009=\u20090.92; 95% CI, 0.86\u2009~\u20090.99;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.03), the incidence of arrhythmia (RR\u2009=\u20090.54; 95% CI, 0.45\u2009~\u20090.64;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), and the length of stay in intensive care unit (ICU) (MD\u2009=\u2009\u2009\u2212\u20091.03; 95% CI,\u2009\u2212\u20091.85 to approximately\u2009\u2212\u20090.21;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.01) than those of the control group. However, there were no statistically significant differences in in-hospital mortality rate (RR\u2009=\u20090.97; 95% CI, 0.90\u2009~\u20091.04;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.4), the 90-day mortality rate (RR\u2009=\u20091.07; 95% CI, 0.97\u2009~\u20091.18;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.15), length of hospital stay (MD\u2009=\u20090.03; 95% CI,\u2009\u2212\u20091.13\u2009~\u20091.18;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.96), and the rate of achieving target MAP (RR\u2009=\u20091.27; 95% CI, 0.72\u2009~\u20092.26;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.41) between the norepinephrine group and the control group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Norepinephrine has the advantages of improving 28-day mortality, shortening ICU hospitalization time, and reducing the incidence of arrhythmia. It is a more effective choice for the treatment of septic shock than other vasopressors, and the incidence of arrhythmia is low.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11845-024-03827-x","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T21:59:30Z","timestamp":1731103170000},"page":"361-369","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Application of norepinephrine in the treatment of septic shock: a meta-analysis"],"prefix":"10.1007","volume":"194","author":[{"given":"Qiu Ying","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Hong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,9]]},"reference":[{"issue":"1","key":"3827_CR1","doi-asserted-by":"publisher","first-page":"e000088","DOI":"10.1136\/tsaco-2017-000088","volume":"2","author":"R Plevin","year":"2017","unstructured":"Plevin R, Callcut R (2017) Update in sepsis guidelines: what is really new? Trauma Surg Acute Care Open 2(1):e000088. https:\/\/doi.org\/10.1136\/tsaco-2017-000088","journal-title":"Trauma Surg Acute Care Open"},{"issue":"1","key":"3827_CR2","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13054-018-2157-z","volume":"22","author":"KE Rudd","year":"2018","unstructured":"Rudd KE, Kissoon N, Limmathurotsakul D and others (2018) The global burden of sepsis: barriers and potential solutions. Crit Care 22(1):232. https:\/\/doi.org\/10.1186\/s13054-018-2157-z","journal-title":"Crit Care"},{"issue":"6","key":"3827_CR3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1001\/jama.2013.13805","volume":"310","author":"CJ Murray","year":"2013","unstructured":"Murray CJ, Atkinson C, Bhalla K and others (2013) The state of US health, 1990\u20132010: burden of diseases, injuries, and risk factors. JAMA 310(6):591\u2013608. https:\/\/doi.org\/10.1001\/jama.2013.13805","journal-title":"JAMA"},{"issue":"3","key":"3827_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5152\/TJAR.2017.93753","volume":"45","author":"F G\u00fcl","year":"2017","unstructured":"G\u00fcl F, Arslanta\u015f MK, Cinel \u0130 and others (2017) Changing definitions of sepsis. Turk J Anaesthesiol Reanim 45(3):129\u2013138. https:\/\/doi.org\/10.5152\/TJAR.2017.93753","journal-title":"Turk J Anaesthesiol Reanim"},{"issue":"9453","key":"3827_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0140-6736(04)17667-8","volume":"365","author":"D Annane","year":"2005","unstructured":"Annane D, Bellissant E, Cavaillon JM (2005) Septic shock. Lancet 365(9453):63\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(04)17667-8","journal-title":"Lancet"},{"issue":"11","key":"3827_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","volume":"47","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W and others (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med 47(11):1181\u20131247. https:\/\/doi.org\/10.1007\/s00134-021-06506-y","journal-title":"Intensive Care Med"},{"issue":"8","key":"3827_CR7","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW and others (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315(8):801\u2013810. https:\/\/doi.org\/10.1001\/jama.2016.0287","journal-title":"JAMA"},{"issue":"3","key":"3827_CR8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","volume":"43","author":"A Rhodes","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W and others (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43(3):304\u2013377. https:\/\/doi.org\/10.1007\/s00134-017-4683-6","journal-title":"Intensive Care Med"},{"issue":"11","key":"3827_CR9","first-page":"11383","volume":"11","author":"L Yin","year":"2018","unstructured":"Yin L, Hou L, Liu R and others (2018) Efficacy of norepinephrine, dopamine or vasopressor in the management of septic shock and severe sepsis: a meta-analysis. Int J Clin Exp Med 11(11):11383\u201311395","journal-title":"Int J Clin Exp Med"},{"issue":"366","key":"3827_CR10","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ and others (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 28(366):l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"issue":"4","key":"3827_CR11","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/bja\/aen017","volume":"100","author":"A Morelli","year":"2008","unstructured":"Morelli A, Ertmer C, Lange M and others (2008) Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. Br J Anaesth 100(4):494\u2013503. https:\/\/doi.org\/10.1093\/bja\/aen017","journal-title":"Br J Anaesth"},{"issue":"4","key":"3827_CR12","doi-asserted-by":"publisher","first-page":"R130","DOI":"10.1186\/cc7990","volume":"13","author":"A Morelli","year":"2009","unstructured":"Morelli A, Ertmer C, Rehberg S and others (2009) Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care 13(4):R130. https:\/\/doi.org\/10.1186\/cc7990","journal-title":"Crit Care"},{"issue":"9588","key":"3827_CR13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S0140-6736(07)61344-0","volume":"370","author":"D Annane","year":"2007","unstructured":"Annane D, Vignon P, Renault A and others (2007) Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 370(9588):676\u2013684. https:\/\/doi.org\/10.1016\/S0140-6736(07)61344-0","journal-title":"Lancet"},{"issue":"4","key":"3827_CR14","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/liv.13252","volume":"37","author":"A Choudhury","year":"2017","unstructured":"Choudhury A, Kedarisetty CK, Vashishtha C and others (2017) A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock. Liver Int 37(4):552\u2013561. https:\/\/doi.org\/10.1111\/liv.13252","journal-title":"Liver Int"},{"issue":"9","key":"3827_CR15","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1056\/NEJMoa0907118","volume":"362","author":"D De Backer","year":"2010","unstructured":"De Backer D, Biston P, Devriendt J and others (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362(9):779\u2013789. https:\/\/doi.org\/10.1056\/NEJMoa0907118","journal-title":"N Engl J Med"},{"issue":"5","key":"3827_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1001\/jama.2016.10485","volume":"316","author":"AC Gordon","year":"2016","unstructured":"Gordon AC, Mason AJ, Thirunavukkarasu N and others (2016) Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 316(5):509\u2013518. https:\/\/doi.org\/10.1001\/jama.2016.10485","journal-title":"JAMA"},{"issue":"12","key":"3827_CR17","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1097\/CCM.0000000000004023","volume":"47","author":"LA Hajjar","year":"2019","unstructured":"Hajjar LA, Zambolim C, Belletti A and others (2019) Vasopressin versus norepinephrine for the management of septic shock in cancer patients: the VANCS II randomized clinical trial. Crit Care Med 47(12):1743\u20131750. https:\/\/doi.org\/10.1097\/CCM.0000000000004023","journal-title":"Crit Care Med"},{"issue":"11","key":"3827_CR18","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1007\/s00134-018-5267-9","volume":"44","author":"ZM Liu","year":"2018","unstructured":"Liu ZM, Chen J, Kou Q and others (2018) Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial. Intensive Care Med 44(11):1816\u20131825. https:\/\/doi.org\/10.1007\/s00134-018-5267-9","journal-title":"Intensive Care Med"},{"issue":"6","key":"3827_CR19","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1378\/chest.103.6.1826","volume":"103","author":"C Martin","year":"1993","unstructured":"Martin C, Papazian L, Perrin G and others (1993) Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 103(6):1826\u20131831. https:\/\/doi.org\/10.1378\/chest.103.6.1826","journal-title":"Chest"},{"issue":"6","key":"3827_CR20","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1186\/cc7121","volume":"12","author":"A Morelli","year":"2008","unstructured":"Morelli A, Ertmer C, Rehberg S and others (2008) Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Crit Care 12(6):R143. https:\/\/doi.org\/10.1186\/cc7121","journal-title":"Crit Care"},{"issue":"12","key":"3827_CR21","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1007\/s00134-008-1219-0","volume":"34","author":"JA Myburgh","year":"2008","unstructured":"Myburgh JA, Higgins A, Jovanovska A and others (2008) A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 34(12):2226\u20132234. https:\/\/doi.org\/10.1007\/s00134-008-1219-0","journal-title":"Intensive Care Med"},{"issue":"4","key":"3827_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/SHK.0b013e3181c6ba6f","volume":"33","author":"GP Patel","year":"2010","unstructured":"Patel GP, Grahe JS, Sperry M and others (2010) Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock 33(4):375\u2013380. https:\/\/doi.org\/10.1097\/SHK.0b013e3181c6ba6f","journal-title":"Shock"},{"issue":"9","key":"3827_CR23","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1164\/rccm.201806-1034OC","volume":"199","author":"C Permpikul","year":"2019","unstructured":"Permpikul C, Tongyoo S, Viarasilpa T and others (2019) Early use of norepinephrine in septic shock resuscitation (CENSER). A randomized trial. Am J Respir Crit Care Med 199(9):1097\u20131105. https:\/\/doi.org\/10.1164\/rccm.201806-1034OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"3827_CR24","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa067373","volume":"358","author":"JA Russell","year":"2008","unstructured":"Russell JA, Walley KR, Singer J and others (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358(9):877\u2013887. https:\/\/doi.org\/10.1056\/NEJMoa067373","journal-title":"N Engl J Med"},{"issue":"4","key":"3827_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/SHK.0b013e3181c6ba6f","volume":"33","author":"JS Patel","year":"2010","unstructured":"Patel JS, Sperry M, Singla S, Elpern E, Lateef O, Balk RA (2010) Efficacy and safety of dopamine versus norepinephrine in the management of septic shock [J]. Randomized Controlled Trial 33(4):375\u2013380. https:\/\/doi.org\/10.1097\/SHK.0b013e3181c6ba6f","journal-title":"Randomized Controlled Trial"},{"issue":"2","key":"3827_CR26","doi-asserted-by":"publisher","first-page":"CD003709","DOI":"10.1002\/14651858.CD003709.pub4","volume":"2","author":"G Gamper","year":"2016","unstructured":"Gamper G, Havel C, Arrich J and others (2016) Vasopressors for hypotensive shock. Cochrane Database Syst Rev 2(2):CD003709. https:\/\/doi.org\/10.1002\/14651858.CD003709.pub4","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"3827_CR27","doi-asserted-by":"publisher","first-page":"e0129305","DOI":"10.1371\/journal.pone.0129305","volume":"10","author":"T Avni","year":"2015","unstructured":"Avni T, Lador A, Lev S and others (2015) Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PLoS ONE 10(8):e0129305. https:\/\/doi.org\/10.1371\/journal.pone.0129305","journal-title":"PLoS ONE"},{"issue":"3","key":"3827_CR28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/0885066610396312","volume":"27","author":"TS Vasu","year":"2012","unstructured":"Vasu TS, Cavallazzi R, Hirani A and others (2012) Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials. J Intensive Care Med 27(3):172\u2013178. https:\/\/doi.org\/10.1177\/0885066610396312","journal-title":"J Intensive Care Med"},{"issue":"6","key":"3827_CR29","doi-asserted-by":"publisher","first-page":"R181","DOI":"10.1186\/cc8167","volume":"13","author":"MW D\u00fcnser","year":"2009","unstructured":"D\u00fcnser MW, Ruokonen E, Pettil\u00e4 V and others (2009) Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Crit Care 13(6):R181. https:\/\/doi.org\/10.1186\/cc8167","journal-title":"Crit Care"},{"issue":"3","key":"3827_CR30","doi-asserted-by":"publisher","first-page":"R97","DOI":"10.1186\/cc13868","volume":"18","author":"V Beck","year":"2014","unstructured":"Beck V, Chateau D, Bryson GL and others (2014) Timing of vasopressor initiation and mortality in septic shock: a cohort study. Crit Care 18(3):R97. https:\/\/doi.org\/10.1186\/cc13868","journal-title":"Crit Care"},{"issue":"6","key":"3827_CR31","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00134-018-5085-0","volume":"44","author":"MM Levy","year":"2018","unstructured":"Levy MM, Evans LE, Rhodes A (2018) The surviving sepsis campaign bundle: 2018 update. Intensive Care Med 44(6):925\u2013928. https:\/\/doi.org\/10.1007\/s00134-018-5085-0","journal-title":"Intensive Care Med"},{"issue":"4","key":"3827_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/00005373-199910000-00014","volume":"47","author":"MB Malay","year":"1999","unstructured":"Malay MB, Ashton RC Jr, Landry DW and others (1999) Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma. 47(4):699\u2013703. https:\/\/doi.org\/10.1097\/00005373-199910000-00014. discussion 703-705","journal-title":"J Trauma."},{"issue":"3","key":"3827_CR33","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/00003246-200103000-00004","volume":"29","author":"I Tsuneyoshi","year":"2001","unstructured":"Tsuneyoshi I, Yamada H, Kakihana Y and others (2001) Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 29(3):487\u2013493. https:\/\/doi.org\/10.1097\/00003246-200103000-00004","journal-title":"Crit Care Med"},{"issue":"5","key":"3827_CR34","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/phar.2105","volume":"38","author":"DA Hammond","year":"2018","unstructured":"Hammond DA, Ficek OA, Painter JT and others (2018) Prospective open-label trial of early concomitant vasopressin and norepinephrine therapy versus initial norepinephrine monotherapy in septic shock. Pharmacotherapy 38(5):531\u2013538. https:\/\/doi.org\/10.1002\/phar.2105","journal-title":"Pharmacotherapy"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-024-03827-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-024-03827-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-024-03827-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T08:04:44Z","timestamp":1740470684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-024-03827-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,9]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3827"],"URL":"https:\/\/doi.org\/10.1007\/s11845-024-03827-x","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,9]]},"assertion":[{"value":"20 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}